Antagonism of the effects of the hallucinogen dom and the purported 5-HT agonist quipazine by 5-HT2 antagonists
Abstract
Rats trained to discriminate 1.0 mg/kg of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM) from saline in a two-lever operant choice task were administered doses of mescaline, LSD, 5-methoxy-N,N-dimethyltryptamine (5-OMe DMT), quipazine, TFMPP and RU-24969. The DOM-stimulus generalized to the three hallucinogenic agents and to quipazine, but not to the purported serotonin agonists TFMPP or RU-24969. Pretreatment of the animals with the 5-HT2 antagonists ketanserin and pirenperone antagonized the effect produced by DOM. Pirenperone also blocked DOM-stimulus generalization to mescaline, LSD, 5-OMe DMT and quipazine. The results of this study suggest that the discriminative stimulus effects of DOM, the three hallucinogenic agents to which DOM-stimulus generalization occurred, and quipazine, may involve those sub-populations of serotonin receptors that are labeled by tritiated ketanserin (i.e. 5-HT2 sites).
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Classic psychedelics are substances that bind to serotonin receptors in the brain with 5HT2A receptor selectivity.
“To prevent any potential numerical errors, the term “classic psychedelics'' is used, referring to the category of substances that bind to serotonin receptors in the brain, with 5HT2A receptor selectivity [29].”
From Mindfulness meditation and psychedelics: potential synergies and commonalities (2023) · cites this paper as [29]
Cites
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
Litchfield, J. T., & Wilcoxon, F. (1949) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03549-9 · Cited by 7,839 · see citing works
Peroutka, S. J., & Snyder, S. H. (1979) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13812-1 · Cited by 1,363 · see citing works
Leysen, J. E., Niemegeers, C. J. E., Nueten, J. M. V., & Laduron, P. M. (1982) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14623-3 · Cited by 1,071 · see citing works
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
Leysen, J. E., Awouters, F. H. L., Kennis, L. E. J., Laduron, P. M., Vandenberk, J., & Janssen, P. A. J. (1981) · Life Sciences · doi:10.1016/0024-3205(81)90747-5 · Cited by 843 · see citing works
Two Distinct Central Serotonin Receptors with Different Physiological Functions
Peroutka, S. J., Lebovitz, R. M., & Snyder, S. H. (1981) · Science · doi:10.1126/science.7221567 · Cited by 639 · see citing works
Colpaert, F. C., Niemegeers, C. J. E., & Janssen, P. A. J. (1982) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)33038-7 · Cited by 168 · see citing works
Green, A. R., Youdim, M. B. H., & Smith, A. D. (1976) · Neuropharmacology · doi:10.1016/0028-3908(76)90026-5 · Cited by 120 · see citing works
Glennon, R. A., Rosecrans, J. A., & Young, R. (1983) · Medicinal Research Reviews · doi:10.1002/med.2610030305 · Cited by 89 · see citing works
Self-citationGREEN, A. R., Hall, J., & Rees, A. R. (1981) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1981.tb16806.x · Cited by 88 · see citing works
DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines
Glennon, R. A., Young, R., Jacyno, J. M., Slusher, M., & Rosecrans, J. A. (1983) · European Journal of Pharmacology · doi:10.1016/0014-2999(83)90196-6 · Cited by 67 · see citing works
Self-citationSerotonin — Current Aspects of Neurochemistry and Function
Strange, P. (1982) · Biochemical Education · doi:10.1016/0307-4412(82)90100-5 · Cited by 60 · see citing works
Fuller, R. W., Snoddy, H. D., Mason, N. R., & Molloy, B. B. (1978) · European Journal of Pharmacology · doi:10.1016/0014-2999(78)90016-x · Cited by 59 · see citing works
Silverman, P. B., & Ho, B. T. (1980) · Psychopharmacology · doi:10.1007/bf00428105 · Cited by 55 · see citing works
Fuller, R. W., Mason, N. R., & Molloy, B. B. (1980) · Biochemical Pharmacology · doi:10.1016/0006-2952(80)90567-5 · Cited by 54 · see citing works
5-Hydroxytryptamine-like properties of m-chlorophenylpiperazine: comparison with quipazine
Rokosz-Pelc, A., Antkiewicz‐Michaluk, L., & Vetulani, J. (1980) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1980.tb12896.x · Cited by 47 · see citing works
Chapter 1. Biochemical Models for Serotonin Receptors
McDermed, J. D., Leysen, J. E., & Tollenaere, J. P. (1982) · Annual reports in medicinal chemistry · doi:10.1016/s0065-7743(08)60483-2 · Cited by 39 · see citing works
Hunt, P., & Oberlander, C. (1981) · Advances in experimental medicine and biology · doi:10.1007/978-1-4684-3860-4_31 · Cited by 38 · see citing works
Discriminative stimulus properties of the hallucinogenic agent DOM.
Young, R., Glennon, R. A., & Rosecrans, J. A. (1980) · PubMed · Cited by 31 · see citing works
Self-citationComparison of behavioral properties of di- and tri-methoxyphenylisopropylamines
Glennon, R. A., & Young, R. (1982) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(82)90330-6 · Cited by 28 · see citing works
Self-citationPharmacological studies on serotonin-mediated behaviour.
Green, A. R. (1981) · PubMed · Cited by 12 · see citing works
Flagged first, then by citations
2 of the 22 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762 · see citing works
Nichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211 · see citing works
Nichols, D. E., & Nichols, C. D. (2008) · Chemical Reviews · doi:10.1021/cr078224o · Cited by 895 · see citing works
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635 · see citing works
Self-citationNichols, D. E. (1986) · Journal of Psychoactive Drugs · doi:10.1080/02791072.1986.10472362 · Cited by 564 · see citing works
Johnson, M. W., Hendricks, P. S., Barrett, F. S., & Griffiths, R. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.010 · Cited by 506 · see citing works
Multiple receptors contribute to the behavioral effects of indoleamine hallucinogens
Halberstadt, A. L., & Geyer, M. A. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.01.017 · Cited by 416 · see citing works
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
Halberstadt, A. L. (2015) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.07.016 · Cited by 312 · see citing works
“…and all legal disclaimers that apply to the journal pertain. anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript hallucinogens produce similar discriminative stimulus effects (Glennon et al., 1982) and act as agonists of the serotonin-2A (5-HT2A) receptor (Glennon et al., 1983).”
BackgroundPsychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/journal.pone.0009019 · Cited by 300 · see citing works
Schmidt, C. J., Levin, J. A., & Lovenberg, W. M. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90729-5 · Cited by 297 · see citing works
The hallucinogenic world of tryptamines: an updated review
Araújo, A. M., Carvalho, F. D., Bastos, M. D. L., de Pinho, P. G., & Carvalho, M. C. (2015) · Archives of Toxicology · doi:10.1007/s00204-015-1513-x · Cited by 292 · see citing works
Halberstadt, A. L., Chatha, M., Klein, A. K., Wallach, J., & Brandt, S. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107933 · Cited by 278 · see citing works
Ugedo, L., Grenhoff, J., & Svensson, T. H. (1989) · Psychopharmacology · doi:10.1007/bf00442004 · Cited by 267 · see citing works
The behavioral pharmacology of hallucinogens
Fantegrossi, W. E., Murnane, K. S., & Reissig, C. J. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.018 · Cited by 226 · see citing works
Serotonergic basis of antipsychotic drug effects in schizophrenia
Lieberman, J. A., Mailman, R. B., Duncan, G., Sikich, L., Chakos, M., Nichols, D. E., & Kraus, J. E. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(98)00187-5 · Cited by 206 · see citing works
Clinical applications of hallucinogens: a review
Garcia-Romeu, A., Kersgaard, B., & Addy, P. H. (2016) · Experimental and Clinical Psychopharmacology · doi:10.1037/pha0000084 · Cited by 201 · see citing works
Arnt, J. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90345-0 · Cited by 200 · see citing works
The promises and perils of psychedelic pharmacology for psychiatry
McClure‐Begley, T. D., & Roth, B. L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00421-7 · Cited by 198 · see citing works
The serotonergic system in Parkinson's disease
Huot, P., Fox, S. H., & Brotchie, J. M. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.004 · Cited by 195 · see citing works
Schmidt, C. J., & Taylor, V. L. (1987) · Biochemical Pharmacology · doi:10.1016/0006-2952(87)90566-1 · Cited by 187 · see citing works
Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials
Fuentes, J. J., Fonseca, F., Elices, M., Farré, M., & Torrens, M. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00943 · Cited by 177 · see citing works
The behavioural response to 5-HT receptor agonists and subtypes of the central 5-HT receptor
Tricklebank, M. D. (1985) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(85)90191-9 · Cited by 168 · see citing works
Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex
Pierce, P. A., & Peroutka, S. J. (1989) · Psychopharmacology · doi:10.1007/bf00443425 · Cited by 152 · see citing works
Substance-Induced Psychoses: An Updated Literature Review
Fiorentini, A., Cantù, F., Crisanti, C., Cereda, G., Oldani, L., & Brambilla, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.694863 · Cited by 146 · see citing works
Kankaanpää, A., Meririnne, E., Lillsunde, P. M., & Seppαlä, T. (1998) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(97)00527-3 · Cited by 140 · see citing works
Fantegrossi, W. E., Ullrich, T., Rice, K. C., Woods, J. H., & Winger, G. D. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1021-6 · Cited by 139 · see citing works
PSD-95 Is Essential for Hallucinogen and Atypical Antipsychotic Drug Actions at Serotonin Receptors
Abbas, A. I., Yadav, P. N., Yao, W.-D., Arbuckle, M. I., Grant, S. G. N., Caron, M. G., & Roth, B. L. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-09.2009 · Cited by 137 · see citing works
Marona‐Lewicka, D., Thisted, R. A., & Nichols, D. E. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2183-9 · Cited by 134 · see citing works
Central serotonin receptors: effector systems, physiological roles and regulation
Conn, P. J., & Sanders‐Bush, E. (1987) · Psychopharmacology · doi:10.1007/bf00210830 · Cited by 133 · see citing works
Serotonin-S2 receptor binding sites and functional correlates
Leysen, J. E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90093-5 · Cited by 132 · see citing works
Sadzot, B., Baraban, J. M., Glennon, R. A., Lyon, R. A., Leonhardt, S., Jan, C.-R., & Titeler, M. (1989) · Psychopharmacology · doi:10.1007/bf00441948 · Cited by 132 · see citing works
Self-citationShannon, M. H., Battaglia, G., Glennon, R. A., & Titeler, M. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90333-9 · Cited by 128 · see citing works
Self-citationRecent developments in 5HT-related pharmacology of animal models of anxiety
Gardner, C. R. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90215-7 · Cited by 126 · see citing works
Brito-da-Costa, A. M., Dias-da-Silva, D., Gomes, N. G. M., Dinis-Oliveira, R. J., & Madureira-Carvalho, Á. (2020) · Pharmaceuticals · doi:10.3390/ph13110334 · Cited by 117 · see citing works
Electrophysiology of the Central Serotonin System: Receptor Subtypes and Transducer Mechanismsa
Aghajanian, G. K., Sprouse, J. S., Sheldon, P. W., & Rasmussen, K. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16875.x · Cited by 117 · see citing works
Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.
Kometer, M., & Vollenweider, F. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_461 · Cited by 88 · see citing works
Effect of Hallucinogens on Unconditioned Behavior
Halberstadt, A. L., & Geyer, M. A. (2016) · Current topics in behavioral neurosciences · doi:10.1007/7854_2016_466 · Cited by 109 · see citing works
Serotonin Receptor Subtypes and Sexual Behaviora
Gorzalka, B. B., Mendelson, S. D., & Watson, N. V. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb16900.x · Cited by 107 · see citing works
Drug-induced penile erections in rats: indications of serotonin1B receptor mediation
Berendsen, H. H. G., & Broekkamp, C. L. E. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90676-5 · Cited by 105 · see citing works
Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors
Buckholtz, N. S., Zhou, D., & Freedman, D. X. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90342-6 · Cited by 106 · see citing works
5HT-2 mediation of acute behavioral effects of hallucinogens in rats
Wing, L. L., Tapson, G. S., & Geyer, M. A. (1990) · Psychopharmacology · doi:10.1007/bf02244617 · Cited by 97 · see citing works
Rasmussen, K., & Aghajanian, G. K. (1986) · Brain Research · doi:10.1016/0006-8993(86)91090-5 · Cited by 103 · see citing works
Pranzatelli, M. R. (1990) · Neuroscience Letters · doi:10.1016/0304-3940(90)90520-j · Cited by 93 · see citing works
“Selective” serotonin 5-HT2A receptor antagonists
Casey, A. B., Cui, M., Booth, R. G., & Canal, C. E. (2022) · Biochemical Pharmacology · doi:10.1016/j.bcp.2022.115028 · Cited by 94 · see citing works
Gorea, E., & Adrien, J. (1988) · European Journal of Pharmacology · doi:10.1016/0014-2999(88)90203-8 · Cited by 91 · see citing works
Leptourgos, P., Fortier, M., Carhart-Harris, R. L., Corlett, P. R., Dupuis, D., Halberstadt, A. L., Kometer, M., Kozáková, E., Larøi, F., Noorani, T. N., et al. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa117 · Cited by 87 · see citing works
Cunningham, K. A., & Appel, J. B. (1987) · Psychopharmacology · doi:10.1007/bf00690929 · Cited by 85 · see citing works
Mendelson, S. D. (1992) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(05)80204-0 · Cited by 84 · see citing works
The Paradox of 5-Methoxy-N,N-Dimethyltryptamine
Winter, J. C., Filipink, R. A., Timineri, D. M., Helsley, S., & Rabin, R. A. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00178-1 · Cited by 79 · see citing works
ECSTACY: A Review of MDMA and MDA
Climko, R. P., Roehrich, H., Sweeney, D. R., & Al-Razi, J. (1987) · The International Journal of Psychiatry in Medicine · doi:10.2190/dcrp-u22m-aumd-d84h · Cited by 78 · see citing works
Hallucinogens as discriminative stimuli in animals: LSD, phenethylamines, and tryptamines
Winter, J. C. (2009) · Psychopharmacology · doi:10.1007/s00213-008-1356-8 · Cited by 65 · see citing works
The role of dopamine and serotonin receptors in the mediation of the ethanol interoceptive cue
Signs, S. A., & Schechter, M. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90424-8 · Cited by 73 · see citing works
Cunningham, K. A., Callahan, P. M., & Appel, J. B. (1987) · European Journal of Pharmacology · doi:10.1016/0014-2999(87)90333-5 · Cited by 72 · see citing works
Zamberlan, F., Sanz, C., Martínez Vivot, R., Pallavicini, C., Erowid, F., Erowid, E., & Tagliazucchi, E. (2018) · Frontiers in Integrative Neuroscience · doi:10.3389/fnint.2018.00054 · Cited by 71 · see citing works
Glennon, R. A. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90461-3 · Cited by 70 · see citing works
Self-citationSpencer, D. G., Gläser, T., & Traber, J. (1987) · Psychopharmacology · doi:10.1007/bf00179927 · Cited by 69 · see citing works
[3H]DOB: A specific agonist radioligand for 5-HT2 serotonin receptors
Titeler, M., Herrick, K. F., Lyon, R. A., MCKENNEY, J. D. J., & Glennon, R. A. (1985) · European Journal of Pharmacology · doi:10.1016/0014-2999(85)90486-8 · Cited by 68 · see citing works
Self-citationEvidence that 5‐HT2receptor activation decreases noradrenaline release in rat hippocampusin vivo
Done, C., & Sharp, T. (1992) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1992.tb14493.x · Cited by 66 · see citing works
Serotonergic Receptor Subtypes and Hallucinogen-Induced Stimulus Control
Winter, J. C., Fiorella, D. J., Timineri, D. M., Filipink, R. A., Helsley, S., & Rabin, R. A. (1999) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(99)00063-5 · Cited by 64 · see citing works
Leysen, J. E. (1984) · Neuropharmacology · doi:10.1016/0028-3908(84)90066-2 · Cited by 63 · see citing works
Habrdová, V., Peters, F. T., Theobald, D. S., & Maurer, H. H. (2005) · Journal of Mass Spectrometry · doi:10.1002/jms.853 · Cited by 62 · see citing works
Glennon, R. A. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90243-1 · Cited by 61 · see citing works
Self-citationCardiovascular safety of psychedelic medicine: current status and future directions
Wsół, A. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00539-4 · Cited by 60 · see citing works
Correction: Psychedelics and the Human Receptorome
Ray, T. S. (2010) · PLoS ONE · doi:10.1371/annotation/e580a864-cf13-40c2-9bd9-b9687a6f0fe4 · Cited by 58 · see citing works
Mianserin treatment of patients with psychosis induced by antiparkinsonian drugs
Ikeguchi, K., & Kuroda, A. (1995) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/bf02190411 · Cited by 57 · see citing works
Leysen, J. E. (2003) · Humana Press eBooks · doi:10.1385/0-89603-122-5:299 · Cited by 56 · see citing works
Johnson, M. P., Mathis, C. A., Shulgin, A. T., Hoffman, A. J., & Nichols, D. E. (1990) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(90)90228-a · Cited by 55 · see citing works
Psychedelics as Transformative Therapeutics
Roth, B. L., & Gumpper, R. H. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230172 · Cited by 54 · see citing works
Discriminative Stimulus Effects of 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane in Rhesus Monkeys
Li, J., Rice, K. C., & France, C. P. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.107.130625 · Cited by 52 · see citing works
Behavioral profile of constituents in ayahuasca, an Amazonian psychoactive plant mixture
Freedland, C. S., & Mansbach, R. S. (1999) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(98)00154-9 · Cited by 51 · see citing works
MDA: A psychoactive agent with dual stimulus effects
Glennon, R. A., & Young, R. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90627-1 · Cited by 49 · see citing works
Self-citationTFMPP may produce its stimulus effects via a 5-HT1B mechanism
MCKENNEY, J. D. J., & Glennon, R. A. (1986) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(86)90042-0 · Cited by 49 · see citing works
Self-citationSerotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action
Canal, C. E. (2018) · Handbook of experimental pharmacology · doi:10.1007/164_2018_107 · Cited by 48 · see citing works
Glennon, R. A., MCKENNEY, J. D. J., & Young, R. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90164-4 · Cited by 47 · see citing works
Self-citationMindfulness meditation and psychedelics: potential synergies and commonalities
Holas, P., & Kamińska, J. (2023) · Pharmacological Reports · doi:10.1007/s43440-023-00551-8 · Cited by 43 · see citing works
“Psychedelics, on the other hand, offer a shortcut to such states, but their effects can be temporary and influenced by external factors [29, [58].”
BackgroundMethodStructure–Activity Relationships of Phenylalkylamines as Agonist Ligands for 5‐HT2A Receptors
Blaazer, A. R., Smid, P., & Kruse, C. G. (2008) · ChemMedChem · doi:10.1002/cmdc.200800133 · Cited by 43 · see citing works
Binding to the serotonin 5-HT2 receptor by the enantiohers of 125I-DOI
Johnson, M. P., Hoffman, A. J., Nichols, D. E., & Mathis, C. A. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90138-9 · Cited by 41 · see citing works
Arnt, J., & Hyttel, J. (1986) · Journal of Neural Transmission · doi:10.1007/bf01243350 · Cited by 41 · see citing works
Mechanistic investigation of the stimulus properties of 1-(3-trifluoromethylphenyl) piperazine
Herndon, J. L., Pierson, M. E., & Glennon, R. A. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90403-3 · Cited by 40 · see citing works
Self-citationMechanistic studies on DOM as a discriminative stimulus
Glennon, R. A., & Hauck, A. E. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90096-6 · Cited by 40 · see citing works
Self-citationWinter, J. C., & Rabin, R. A. (1988) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(88)90074-3 · Cited by 40 · see citing works
Bioactive Alkaloids of Hallucinogenic Mushrooms
Wieczorek, P. P., Witkowska, D., Jasicka-Misiak, І., Poliwoda, A., Oterman, M., & Zielińska, K. (2015) · Studies in natural products chemistry · doi:10.1016/b978-0-444-63462-7.00005-1 · Cited by 40 · see citing works
Complex discriminative stimulus properties of (+)lysergic acid diethylamide (LSD) in C57Bl/6J mice
Benneyworth, M. A., Smith, R. L., Barrett, R. J., & Sanders‐Bush, E. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2108-z · Cited by 38 · see citing works
Darmani, N. A., Mock, O. B., Towns, L. C., & Gerdes, C. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90542-8 · Cited by 38 · see citing works
Serotonergic modulation of the discriminative-stimulus effects of cocaine in squirrel monkeys
Schama, K. F., Howell, L. L., & Byrd, L. D. (1997) · Psychopharmacology · doi:10.1007/s002130050316 · Cited by 38 · see citing works
Serotonin type 2 antagonists inhibit lordosis behavior in the female rat: Reversal with quipazine
Mendelson, S. D., & Gorzalka, B. B. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90272-9 · Cited by 38 · see citing works
Site-Selective Serotonin Agonists as Discriminative Stimuli
Glennon, R. A. (1988) · Springer eBooks · doi:10.1007/978-3-642-73223-2_2 · Cited by 37 · see citing works
Self-citationSerotonin antagonist pirenperone inhibits sexual behavior in the male rat: Attenuation by quipazine
Mendelson, S. D., & Gorzalka, B. B. (1985) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(85)90276-x · Cited by 36 · see citing works
Grome, J. J., & Harper, A. M. (1986) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1986.tb12933.x · Cited by 39 · see citing works
Hansen, M., Jacobsen, S. E., Plunkett, S., Liebscher, G., McCorvy, J. D., Bräuner‐Osborne, H., & Kristensen, J. L. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.12.011 · Cited by 35 · see citing works
Glennon, R. A., Higgs, R., Young, R., & Issa, H. (1992) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(92)90488-2 · Cited by 35 · see citing works
Self-citationInvolvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline
Appel, J. B., & Callahan, P. M. (1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90041-1 · Cited by 34 · see citing works
Behavioral Models of Serotonin Receptor Activation
Glennon, R. A., & Lucki, I. (1988) · Humana Press eBooks · doi:10.1007/978-1-4612-4560-5_9 · Cited by 33 · see citing works
Self-citationWulff, A. B., Nichols, C. D., & Thompson, S. M. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109504 · Cited by 34 · see citing works
Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan
Marona‐Lewicka, D., & Nichols, D. E. (1994) · European Journal of Pharmacology · doi:10.1016/0014-2999(94)90051-5 · Cited by 31 · see citing works
Dukat, M., Young, R., Darmani, N. N., Ahmed, B., & Glennon, R. A. (2000) · Psychopharmacology · doi:10.1007/s002130000410 · Cited by 30 · see citing works
Self-citationHelsley, S., Fiorella, D. J., Rabin, R. A., & Winter, J. C. (1998) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(98)00031-1 · Cited by 29 · see citing works
Philibin, S. D., Prus, A. J., Pehrson, A. L., & Porter, J. H. (2005) · Psychopharmacology · doi:10.1007/s00213-005-2147-0 · Cited by 29 · see citing works
Roth, B. L., Willins, D. L., Kristiansen, K., & Kroeze, W. K. (1999) · The Neuroscientist · doi:10.1177/107385849900500414 · Cited by 28 · see citing works
Pogorelov, V. M., Rodriguiz, R. M., Roth, B. L., & Wetsel, W. C. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1233743 · Cited by 30 · see citing works
- Authors
- Glennon, R. A., Young, R., & Rosecrans, J. A.
- Affiliations
- Virginia Commonwealth University (US)
- Corresponding author
- Glennon, Richard A.
- Venue
- European Journal of Pharmacology
- Publisher
- Elsevier BV
- Published
- 1983-07
- Volume
- 91
- Issue
- 2-3
- Pages
- 189-196
- ISSN
- 0014-2999 (ISSN-L)
- OpenAlex
- W1983135802
- Cited by
- 190
- References
- 22
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 5 · 2023: 7 · 2022: 6 · 2021: 2 · 2020: 7 · 2019: 1 · 2018: 5 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3
- FWCI
- 15.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Keywords
- DOM, 5-HT2 receptor antagonist, quipazine, ketanserin, pirenperone, mescaline, LSD, hallucinogens, TFMPP, RU 24969, serotonin receptor agonists
- MeSH terms
- Amphetamines, Animals, DOM 2,5-Dimethoxy-4-Methylamphetamine, Ketanserin, Male, Piperidines, Quinolines, Quipazine, Rats, Inbred Strains, Serotonin Antagonists, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review